In Reply We thank Bergquist and colleagues for their interest in our article1 on the association of aspirin use with biliary tract cancer (BTC) survival in the UK’s Clinical Practice Research Datalink (CPRD). We agree that the results cannot be the sole justification to incorporate aspirin therapy into the standard management of BTCs. For that, careful replication of the findings and, if possible, a randomized clinical trial are needed to provide further evidence. We also agree that the analysis has limitations that are typical with the use of electronic databases for observational research. We appreciate the opportunity to respond to these limitations beyond what was discussed in our article.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Jackson SS, Pfeiffer RM, Koshiol J. Questionable Survival Benefit of Aspirin Use in Patients With Biliary Tract Cancer—Reply. JAMA Oncol. 2020;6(5):784. doi:10.1001/jamaoncol.2020.0125
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.